Financial News Feed

Stronger Sell Today VTGN ranks #4242 as SELL CANDIDATE. Weaker Sell
Today VTGN ranks #4242 as SELL CANDIDATE.

VTGN stock VistaGen Therapeutics Inc

VTGN stock
VistaGen Therapeutics Inc

Oppenheimer analyst Jay Olson maintained a Hold rating on VistaGen Therapeutics (VTGN) on March 15. The company’s shares opened today at $1. The post VistaGen Therapeutics (VTGN) Gets a Hold Rating ...

Read more

Company shares of Vistagen Therap. Com (VTGN) have seen the Rank Correlation Indicator climb higher over the past 3 trading days, suggesting that it could be nearing a turning point if the reading cro...

Read more

Checking in on the short-term signals on Vistagen Therap. Com (VTGN), we note that the current 7-day average directional indicator is Buy. This signal may be used to determine the market trend. The 7-...

Read more

Vistagen Therap. Com (VTGN) has ended the week in the black, yielding positive results for the shares at they ticked 9.48%. In taking a look at recent performance, we can see that shares have moved -2...

Read more

Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe bought 12,080 shares of the stock in a transaction that occurred on Wednesday, March 13th. The stock was bought at an average price of $1.2...

Read more

Watching the technical levels for Vistagen Therap. Com (VTGN), we have spotted that the SuperTrend line is currently sitting above recent share price levels. According to the signal, this may point to...

Read more

Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe acquired 12,080 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were bought at an average price of...

Read more

Shares of Vistagen Therap. Com (VTGN) are on watch as the Tenkan Line has moved below the Kijun line, indicating negative momentum for the equity. Vistagen Therap. Com moved 0.02 in the most recent se...

Read more

Today, a Director at VistaGen Therapeutics (VTGN), Jon Saxe, bought shares of VTGN for $25.16K. The post A Director at VistaGen Therapeutics (VTGN) is Buying Shares appeared first on Smarter Analyst ....

Read more

Today it was reported that the PRES. of VistaGen Therapeutics (VTGN), Ralph Snodgrass, exercised options to buy 2,500 VTGN shares at $1. The post The PRES. of VistaGen Therapeutics is Exercising Optio...

Read more

Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe purchased 12,080 shares of the firm’s stock in a transaction on Wednesday, March 13th. The shares were purchased at an average cost of $1...

Read more

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure. On March 13, 2019, VistaGen Therapeutics, Inc. (the“Company”)began utilizing a new...

Read more

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other......

Read more

Putting the focus on shares of Vistagen Therap. Com (VTGN) we have noted that the stock price has dropped -28.57% over the last month. Looking back over the last half-year, we can see that the stock h...

Read more

Traders may already have a favorite method for applying technical analysis. Active traders are typically concerned with shorter-term price movements when trading shares. Entry and exit points tend to ...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank